Biotie Therapies
Product pipeline

Biotie Therapies

Section Title: Product pipeline
Table Section Text: None

Name	Target indications	Partner	Status

Selincro (nalmefene)	alcohol dependence	Lundbeck	EU marketing authorization received

Tozadenant SYN115	Parkinson's disease	UCB	Phase III clinical trials to start 2015

VAP-1 antibody	inflammatory diseases	Phase I clinical trials ready, seeking partner

SYN120	AD, cognitive disorders	Phase I clinical trials ready, seeking partner

Nepicastat SYN117	PTSD, cocaine dependency	NIDA	PTSD: Phase II clinical trials, results Cocaine dependency: Phase II clinical trials, in progress

Ronomilast	COPD	Phase I clinical trials ready, seeking partner

Nitisinone SYN118	Movement disorder	UCB	Phase II clinical trials, terminated

Sources:

Sentence(s)

Tozadenant SYN115 is developed for Parkinson's disease.

final_sentence: Tozadenant SYN115 is developed for Parkinson's disease.